Romero-Clarà Olga, Madrid Clara, Pardo Juan Carlos, Ruiz de Porras Vicenç, Etxaniz Olatz, Moreno-Alonso Deborah, Font Albert
e-oncología Online Training Unit, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.
Medical Oncology Department, Catalan Institute of Oncology, Barcelona, Spain.
Front Pharmacol. 2024 Aug 22;15:1380954. doi: 10.3389/fphar.2024.1380954. eCollection 2024.
The high incidence and mortality rates of urothelial carcinoma mean it remains a significant global health concern. Its prevalence is notably pronounced in industrialized countries, with Spain registering one of the highest incidences in Europe. Treatment options are available for various stages of bladder cancer. Moreover, the management landscape for this disease has been significantly transformed by the rapid advances in immunotherapy. Healthcare professionals who diagnose, treat, and follow up with bladder cancer patients need comprehensive training to incorporate these advances into their clinical practice. To bridge these knowledge gaps, we set up the E-PIMUC program to educate healthcare professionals on bladder cancer management and specifically immunotherapy.
E-PIMUC used an innovative microlearning methodology comprising bitesize learning pills that support efficient acquisition of specialized expertise. We used a mixed methods, quantitative and qualitative approach to assess the success of the E-PIMUC program. Data collection encompassed pre-post testing, participation metrics, satisfaction surveys, and self-perceived performance assessments.
A total of 751 healthcare professionals enrolled in the program. Of these, 81.0% actively engaged with the content and 33.2% passed all tests and were awarded the course certificate and professional credits. The course received satisfaction ratings of 94.3% to 95.1% and significantly improved the declarative knowledge of participants who had a range of professional profiles ( < 0.001). Participants reported increased confidence in applying immunotherapy principles in their practice (average improvement of 1.4 points). Open-ended responses also underscored participants' perceived benefits, including expanded knowledge and enhanced patient interaction skills.
The E-PIMUC program provided effective, comprehensive, cutting-edge training on bladder cancer management, particularly on the use of immunotherapy in this area of oncology. The high participation rates, positive satisfaction scores, substantial knowledge enhancement, and improved self-perceived performance, are all testament to the program's success. E-PIMUC was endorsed by regulatory bodies as a trusted educational resource in urothelial carcinoma management. What is more, complementary initiatives brought together patients and medical experts to foster a holistic, patient-centered approach to the complexities of bladder cancer care.
尿路上皮癌的高发病率和死亡率意味着它仍然是一个重大的全球健康问题。其患病率在工业化国家尤为明显，西班牙是欧洲发病率最高的国家之一。膀胱癌的各个阶段都有相应的治疗选择。此外，免疫疗法的迅速发展极大地改变了这种疾病的治疗格局。诊断、治疗和随访膀胱癌患者的医疗保健专业人员需要全面的培训，以便将这些进展纳入临床实践。为了弥补这些知识差距，我们设立了E-PIMUC项目，以教育医疗保健专业人员如何管理膀胱癌，特别是免疫疗法。
E-PIMUC采用了一种创新的微学习方法，包括支持高效获取专业知识的小块学习内容。我们使用了混合方法，即定量和定性方法来评估E-PIMUC项目的成功与否。数据收集包括前后测试、参与指标、满意度调查和自我感知的绩效评估。
共有751名医疗保健专业人员报名参加了该项目。其中，81.0%的人积极参与了学习内容，33.2%的人通过了所有测试，并获得了课程证书和专业学分。该课程的满意度评分在94.3%至95.1%之间，显著提高了具有不同专业背景的参与者的陈述性知识（<0.001）。参与者报告说在实践中应用免疫疗法原则的信心有所增强（平均提高1.4分）。开放式回答也强调了参与者所感受到的益处，包括知识的扩展和患者互动技能的提高。
E-PIMUC项目提供了关于膀胱癌管理，特别是该肿瘤领域免疫疗法使用的有效、全面和前沿的培训。高参与率、积极的满意度评分、知识的大幅提升以及自我感知绩效的改善，都证明了该项目的成功。E-PIMUC被监管机构认可为尿路上皮癌管理方面值得信赖的教育资源。此外，互补性举措将患者和医学专家聚集在一起，以促进对膀胱癌护理复杂性采取整体的、以患者为中心的方法。
